A5034676429- BRCA gene mutations in cancer
- Ovarian cancer diagnosis and treatment
- Cancer Risks and Factors
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- PARP inhibition in cancer therapy
- Reproductive Biology and Fertility
- Global Cancer Incidence and Screening
- Biomedical Text Mining and Ontologies
- Lung Cancer Research Studies
- Machine Learning in Healthcare
- HER2/EGFR in Cancer Research
- Male Breast Health Studies
- Colorectal Cancer Screening and Detection
- AI in cancer detection
- Cancer Immunotherapy and Biomarkers
- Ovarian function and disorders
- Lung Cancer Treatments and Mutations
Assistance Publique – Hôpitaux de Paris
2020-2023
Université Paris Cité
2020-2023
Inserm
2023
Hôpital Saint-Louis
2020-2022
Institut Curie
2019-2022
Délégation Paris 7
2020
Université Paris Sciences et Lettres
2019
Hôpital René Huguenin
2018
Aix-Marseille Université
2018
5558 Background: To investigate clinical factors predictive for prolonged progression-free survival (PFS) in ovarian cancer (OC) patients carrying BRCA mutations and receiving olaparib as a maintenance therapy. Methods: Multicentric (7 centers) international (France Switzerland) retrospective study of OC having germline or somatic BRCA1/BRCA2 genes treated with therapy after platinum-based chemotherapy. Results: One hundred fifteen were included. Median age was 60 years. There 92 BRCA1...
Female breast cancer (BC) patients exposed to gonadotoxic chemotherapy are at risk of future infertility. There is evidence disparities in the discussion fertility preservation for these patients. The aim study was identify factors influencing (FP).We analyzed consecutive BC treated by Institut Curie from 2011-2017 and aged 18-43 years diagnosis. FP classified a binary manner (discussion/no discussion), based on mentions present patient's electronic health record (EHR) before initiation...
While the emergence of large administrative claims data provides opportunities for research, their use remains limited by lack clinical annotations relevant to disease outcomes, such as recurrence in breast cancer (BC). Several challenges arise from annotation endpoints claims, including need infer both occurrence and date recurrence, right-censoring data, or importance time intervals between medical visits. Deep learning approaches have been successfully used label temporal sequences, but...